Condition
Mesothelioma
Estimated Enrollment: 30
Age Group: 18 Years to 100 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment
Study ID Numbers: 160127|16-C-0127
Study First Received: June 10, 2016
Last Updated: April 20, 2017
Estimated Primary Completion Date: August 6, 2018
Primary Outcome Measures:
maximum tolerated dose|proportion of patients at MTD with paartial or complete response per RECIST|average time from treatment initiaition to disease progression or death|average time from start of treatment to death|pharmacokenetic characteristics|number of cycles LMB-100 can be given before ADAs develop|listing and frequency of treatment related adverse events
Sponsors and Collaborators:
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Website Link: https://ClinicalTrials.gov/show/NCT02798536
